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Introduction
Familial Mediterranean Fever (FMF), is the second com-
monest autoinflammatory disease in pediatric Greek
patients (pts) after PFAPA. So far, long-term follow-up
case series in Greek FMF pts have not been emerged.
Objectives
To depict: a) the clinical phenotype, the genotype-pheno-
type interplay and b) the response to treatment and the
long-term outcome in a large series of Greek FMF pts.
Patients and methods: Seventy children (46 females)
with established FMF according to Tel Hashomer classifi-
cation criteria were enrolled in this retrospective study. Pts
were followed-up over a 30-year period (1986-2015) and
most of them underwent a genetic molecular analysis
using either FMF strip assay (Vienna Lab) or NIRCA or
recently NGS.
Results
The mean age at FMF onset was 3.54 years (range 0.83-
18.5), the mean lag time 36.72 months (range 91-185) and
the cumulative follow-up time 731.53 years (9.88/pt). A
positive family history was recorded in 27/70 pts (38.6%).
In respect to phenotype, a typical phenotype was
recorded in 75.7%; the commonest manifestations at
onset were periodic fevers (100%), abdominal pain
(84.3%), rheumatic attacks (arthritis or arthralgias in
52.85%) and chest pain (40%), while monosymptomatic
were only 5.7%. Genotyping studies traced ≥ 1mutation
in 63/67 pts; compound heterozygotes or homozygotes
were 22 and 13 pts respectively. The commonest muta-
tions were M694V (51.6%) and M680I (38.7%), the com-
bination M694V/M680I, the most frequent one (19%)
and M694V was significantly correlated with rheumatic
manifestations (p=0.003). A complete or partial response
to colchicine was recorded in 51.5% and 42.4% respec-
tively, whereas unresponsiveness was observed in 6%.
One refractory patient responded to anti-IL1b adminis-
tration and no patient ever developed amyloidosis.
Conclusions
In this case series, the FMF phenotype in N. Greece was a
typical one and not differential from other Caucasian eth-
nicities, although it was milder and absent of amyloidosis.
The genotype distribution was in line with previously
described mutations in other Mediterranean Countries.
The systemic follow-up and contemporary management in
an organized Center hinders non-compliance and contri-
butes to an optimal disease outcome.
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